Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $12.3050 (-0.53%) ($12.3050 - $12.3050) on Wed. Dec. 14, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.94% (three month average) | RSI | 65 | Latest Price | $12.3050(-0.53%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.2% a day on average for past five trading days. | Weekly Trend | FOLD advances 1.9% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(44%) IWM(43%) IWC(42%) IWN(41%) | Factors Impacting FOLD price | FOLD will decline at least -1.47% in a week (0% probabilities). VXX(-12%) VIXM(-12%) XLU(-10%) TLT(-7%) ARKG(-7%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.47% (StdDev 2.94%) | Hourly BBV | 1.1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $12.12(1.53%) | 10 Day Moving Average | $12.24(0.53%) | 20 Day Moving Average | $11.82(4.1%) | To recent high | -3.2% | To recent low | 23.1% | Market Cap | $3.177b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |